Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Fulvestrant Followed by Everolimus Plus Exemestane vs Examestane and Everolimus Followed by Fulvestrant in Postmenopausal Women With HR+ and HER2- Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) Previously Treated With NSAI

NCT02404051 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT02404051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02404051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Fulvestrant Followed by Everolimus Plus Exemestane vs Examestane and Everolimus Followed by Fulvestrant in Postmenopausal Women With HR+ and HER2- Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) Previously Treated With NSAI
Lead sponsor
Consorzio Oncotech
Phase
Phase 3
Overall status
Unknown status
Start date
December 31, 2015
Completion date
January 31, 2019
Enrollment
745 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hormone receptor positive tumor, human epidermal growth factor 2 negative carcinoma of breast, locally advanced malignant neoplasm, metastatic breast cancer